Augmentation of HIV-1-specific T helper cell responses in chronic HIV-1 infection by therapeutic immunization

AIDS

Volumn 17, Issue 8, 2003, Pages 1121-1126

  Robbins, Gregory K ^a   Addo, Marylyn M ^a   Troung, Hien ^a   Rathod, Almas ^a   Habeeb, Kathy ^a   Davis, Benjamin ^a   Heller, Howard ^a   Basgoz, Nesli ^a   Walker, Bruce D ^a,b   Rosenberg, Eric S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Partners AIDS Research Center   (United States)

Author keywords

AIDS; HIV; Immunology; Lymphoproliferation; T helper cells; Therapeutic vaccine

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; FREUND ADJUVANT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INACTIVATED VACCINE; PLACEBO; PROTEINASE;

ARTICLE; CELL COUNT; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; DOUBLE BLIND PROCEDURE; FEMALE; FISHER EXACT TEST; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; LYMPHOCYTE PROLIFERATION; MALE; PLASMA; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; RNA VIRUS; TREATMENT OUTCOME; VIRUS ENVELOPE; VIRUS LOAD;

ADULT; AIDS VACCINES; CD4 LYMPHOCYTE COUNT; CHRONIC DISEASE; CYTOTOXICITY, IMMUNOLOGIC; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION; MALE; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 0038205366     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200305230-00002     Document Type: Article

References (29)

1. Zajac AJ, Murali-Krishna K, Blattman JN, Ahmed R. Therapeutic vaccination against chronic viral infection: the importance of cooperation between CD4+ and CD8+ T cells. Curr Opin Immunol 1998; 10:444-449.
2. Miedema F, Meyaard L, Koot M, Klein MR, Roos MT, Groenink M, et al. Changing virus-host interactions in the course of HIV-1 infection. Immunol Rev 1994; 140:35-72.
3. Lisziewicz J, Rosenberg E, Lieberman J, Jessen H, Lopalco L, Siliciano R, et al. Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med 1999; 340:1683.
4. Blankson JN, Gallant JE, Siliciano RF. Proliferative responses to human immunodeficiency virus type 1 (HIV-1) antigens in HIV-1-infected patients with immune reconstitution. J Infect Dis 2001; 183:657-661.
5. Angel JB, Kumar A, Parato K, Filion LG, Diaz-Mitoma F, Daftarian P, et al. Improvement in cell-mediated immune function during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir. J Infect Dis 1998; 177:898-904.
6. Carcelain G, Tubiana R, Samri A, Calvez V, Delaugerre C, Agut H, et al. Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection. J Virol 2001; 75:234-241
7. Garcia F, Plana M, Soriano A, Vidal C, Arnedo M, Gil C, et al. Predictors of progression in chronically infected naive patients with plasma viraemia below 5000 copies/ml and CD4 T lymphocytes greater than 500 x 10(6)/I. AIDS 2001; 15:131-133.
8. Ruiz L, Martinez-Picado J, Romeu J, Paredes R, Zayat MK, Marfil S, et al. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. AIDS 2000; 14:397-403.
9. Papasavvas E, Ortiz GM, Gross R, Sun J, Moore EC, Heymann JJ, et al. Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption. J Infect Dis 2000; 182:766-775.
10. Trauger RJ, Ferre F, Daigle AE, Jensen FC, Moss RB, Mueller SH, et al. Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type 1 (HIV-1) immunogen on HIV-1 immunity, viral DNA, and percentage of CD4 cells. J Infect Dis 1994; 169:1256-1264.
11. Moss RB, Giermakowska W, Lanza P, Turner JL, Wallace MR, Jensen FC, et al. Cross-clade immune responses after immunization with a whole-killed gp120-depleted human immunodeficiency virus type-1 immunogen in incomplete Freund's adjuvant (HIV-1 immunogen, REMUNE) in human immunodeficiency virus type-1 seropositive subjects. Viral Immunol 1997; 10:221-228.
12. Churdboonchart V, Moss RB, Sirawaraporn W, Smutharaks B, Sutthent R, Jensen FC, et al. Effect of HIV-specific immune-based therapy in subjects infected with HIV-1 subtype E in Thailand. AIDS 1998; 12:1521-1527.
13. Limsuwan A, Churdboonchart V, Moss RB, Sirawaraporn W, Sutthent R, Smutharaks B, et al. Safety and immunogenicity of REMUNE in HIV-infected Thai subjects. Vaccine 1998; 16:142-149.
14. Moss RB, Wallace MR, Giermakowska WK, Webb E, Savary J, Chamberlin-Brandt C, et al. Phenotyplc analysis of human immunodeflclency virus (HIV) type 1 cell-mediated immune responses after treatment with an HIV-1 immunogen. J Infect Dis 1999; 180:641-648.
15. Moss RB, Giermakowska WK, Wallace MR, Savary JR, Jensen FC, Carlo DJ. Cell-mediated immune responses to autologous virus in HIV-1-seropositive individuals after treatment with an HIV-1 immunogen. AIDS 2000; 14:2475-2478.
16. Moss RB, Webb E, Giermakowska WK, Jensen FC, Savary JR, Wallace MR, et al. HIV-1-specific CD4 helper function in persons with chronic HIV-1 infection on antiviral drug therapy as measured by ELISPOT after treatment with an inactivated, gp120-depleted HIV-1 in incomplete Freund's adjuvant. J Acquir Immune Defic Syndr 2000; 24:264-269.
17. Moss RB, Giermakowska W, Wallace MR, Savary J, Jensen F, Carlo DJ. T-helper-cell proliferative responses to whole-killed human immunodeficiency virus type 1 (HIV-1) and p24 antigens of different clades in HIV-1-infected subjects vaccinated with HIV-1 immunogen (Remune). Clin Diagn Lab Immunol 2000; 7:724-727.
18. Sei S, Sandelli SL, Theofan G, Ratto-Kim S, Kumagai M, Loomis-Price LD, et al. Preliminary evaluation of human immunodeficiency virus type I (HIV-1) immunogen in children with HIV-1 infection. J Infect Dis 1999; 180:626-640.
19. Moss RB, Giermakowska WK, Diveley JP, Savary JR, Wallace MR, Maigetter RZ, et al. CXCR4 and CCR5 expression on CD4+ T cells in vivo and HIV-1 antigen beta-chemokine production in vitro after treatment with HIV-1 immunogen (REMUNE). J Hum Virol 2000; 3:44-49.
20. Maino VC, Suni MA, Wormsley SB, Carlo DJ, Wallace MR, Moss RB. Enhancement of HIV type 1 antigen-specific CD4+ T cell memory in subjects with chronic HIV type 1 infection receiving an HIV type I immunogen. AIDS Res Hum Retroviruses 2000; 16:539-547.
21. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997; 278:1447-1450.
22. Addo MM, Altfeld M, Rosenberg ES, Eldridge RL, Philips MN, Habeeb K, et al. The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals. Proc Natl Acad Sci USA 2001; 98:1781-1786.
23. Schwartz D, Sharma U, Busch M, Weinhold K, Matthews T, Lieberman J, et al. Absence of recoverable infectious virus and unique immune responses in an asymptomatic HIV+ long-term survivor. AIDS Res Hum Retroviruses 1994; 10:1703-1711.
24. Turner JL, Trauger RJ, Daigle AE, Carlo DJ. HIV-1 immunogen induction of HIV-1-specific delayed-type hypersensitivity: results of a double-blind, adjuvant-controlled, dose-ranging trial. AIDS 1994; 8:1429-1435.
25. Altfeld M, Rosenberg ES, Shankarappa R, Mukherjee JS, Hecht FM, Eldridge RL, et al. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med 2001; 193:169-180.
26. Kahn JO, Cherng DW, Mayer K, Murray H, Lagakos S. Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 x 10(6)/L CD4 cell counts: a randomized controlled trial. JAMA 2000; 284:2193-2202.
27. Amara RR, Villinger F, Altman JD, Lydy SL, O'Neil SP, Staprans SI, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001; 292:69-74.
28. Barouch DH, Santra S, Schmitz JE, Kuroda MJ, Fu TM, Wagner W, et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000; 290:486-492.
29. Rosenberg ES, Altfeld M, Poon SH, Phillips MN, Wilkes BM, Eldridge RL, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000; 407:523-526.